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Background: Extrinsic allergic alveolitis (EAA) and idiopathic pulmonary fibrosis (IPF) share the
presence of varying degree interstitial involvement and fibrosis. Vascular changes were often
reported to accompany the development of fibrosis.
Objectives: The aim of our study was to examine the differences in angiostatic and angiogenic
chemokine milieu in both diseases. Correlations between chemokine levels in bronchoalveolar
lavage fluid (BALF), expression of chemokine receptors on CD4þ T cells (CXCR2, CXCR3) in BALF
and HRCT pattern of the diseases were investigated.
Methods: Sixteen patients with chronic EAA and 8 with IPF were enrolled to the study. Concen-
trations of interleukin (IL)-8, epithelial neutrophil activating protein (ENA)-78, interferon-g-
inducible protein (IP)-10 and interferon-inducible T cell alpha chemoattractant (I-TAC) in BALF
supernatants were quantified using Fluorokine MultiAnalyte profiling.
Results: There was no significant difference in the BALF chemokine levels between the EAA
and IPF group. IL-8 BALF concentrations correlate with the extent of fibrosis in both EAA
and IPF (p< 0.01). The IP-10 BALF concentrations do not correlate either with the HRCT alve-
olar or interstitial score and should be evaluated in the relationship with the disease course.
Conclusions: Both IL-8 and ENA-78 probably play a different role in IPF and chronic EAA path-
ogenesis. While we suggest ENA-78 as the marker of at least partial reversibility of the lung61 082 625; fax: þ420 261 082 206.
@seznam.cz (S. Martina).
9 Elsevier Ltd. All rights reserved.
1652 S. Martina et al.impairment in the EAA patients, IL-8 could be rather an indicator of continuous exposition to
provoking agent in EAA patients. IL-8 might serve as a potential marker of early phase of IPF.
ª 2009 Elsevier Ltd. All rights reserved.Introduction
Extrinsic allergic alveolitis (EAA, hypersensitivity pneumo-
nitis) and idiopathic pulmonary fibrosis (IPF) are interstitial
lung diseases. They have different etiology and clinical
features, but each of them may lead to end-stage fibrosis.
EAA and IPF share a common feature e the presence of
varying degree of alveolar and interstitial involvement and
fibrosis, which may be quantified with the means of high
resolution computed tomography (HRCT). Angiogenesis was
found to be a critical biological event that accompanies
fibroplasia and deposition of extracellular matrix in the
lung in the course of pulmonary fibrosis.1 It is regulated by
both angiogenic and angiostatic factors. The large family of
CXC chemokines family (four conserved cysteine amino acid
residues with the first two cysteines separated by one
nonconserved amino acid residue) contains members that
exhibit angiogenic and angiostatic activity. Interleukin 8
(IL-8/CXCL8) and epithelial neutrophil activating protein
(ENA)-78 (ENA-78/CXCL5) are the angiogenic members.
They share the same receptor CXCR2. Angiostatic CXC
chemokines include platelet factor-4/CXCL4, monokine
induced by interferon (IFN)-g (MIG/CXCL9), IFN-g-inducible
protein 10 (IP-10/CXCL10) and interferon-inducible T cell
alpha chemoattractant (I-TAC/CXCL11). These angiostatic
CXC chemokines specifically bind to the receptor CXCR3.2
Both angiostatic and angiogenic chemokines were docu-
mented to have pivotal role in pathogenesis of IPF.3
Angiostatic and angiogenic chemokines are also known to
play important role in the development of fibrosis in EAA
patients.4 The aim of our study was to examine if there is
different angiogenic/angiostatic chemokine milieu in the
chronic EAA and IPF patients. Since new therapeutical
options are approaching (e.g. CXCR2 inhibitor reparixin),
knowledge of pathogenetic events leading to lung fibrosis
may help us to treat our patients. Correlation between
chemokine concentrations or chemokine receptor expres-
sion and HRCT score might help us to find new biomarkers,
which could help us to monitor degree of lung fibrosis or
select patients with unfavourable prognosis.
We investigated correlation between chemokine levels
(ENA-78, IL-8, I-TAC, IP-10) in bronchoalveolar lavage fluid
(BALF), expression of chemokine receptors on CD4þ T cells
(CXCR2, CXCR3) in BALF and HRCT pattern (alveolar versus
interstitial HRCT score).Material and methods
Study design
Twenty-four patients with mean age of 62 years (range 27e
81 years) were prospectively enrolled to the study e after
signing informed consent approved by Ethics committee of
the Institute for Clinical and Experimental Medicine andFaculty Thomayer Hospital. None of the patients included
in this study had previously been treated with steroids. A
diagnosis of idiopathic pulmonary fibrosis/usual interstitial
pneumonitis (IPF/UIP) was established in 8 patients. Four
patients were unable to undergo lung biopsy for different
reasons and they were diagnosed IPF by the use of clinical
criteria (ATS/ERS joint statement criteria).5 Sixteen
patients were diagnosed chronic EAA. There are no gener-
ally accepted diagnostic criteria for EAA.6 Diagnostic
criteria applied in our department include a history of
exposition to suspect antigen, symptoms, physical findings,
radiographic abnormalities, pulmonary function, immuno-
logic tests, and BAL results. A lung biopsy specimen is
required when the diagnosis is not definite (2 EAA patients
in our study). Basic spirometry investigation (flow-volume
spirogram, machine ZAN 100 Messgerate GmbH) and diffuse
lung capacity investigation (single breath method, machine
ZAN 300 Messgerate GmbH) were performed in all
subjects.7 A control group could not be included in the
study because of ethical reasons.
All patients underwent bronchoscopy including BAL with
the cytologic and cytometric examination of BALF and
HRCT of the chest. BALF supernatants were frozen at e
80 C and processed later.
Methods
Bronchoalveolar lavage (BAL), cytologic and cytometric
analysis of BAL fluid
BAL was performed according to the technical recommen-
dations and guidelines for the standardization of BAL
procedures.8 Briefly, BAL was performed with a flexible
bronchoscope (Olympus, Olympus Optical CO, Ltd., Japan)
wedged into segmental or subsegmental middle lobe
bronchus. Five 50 ml aliquots of sterile 0.9% saline solution
were instilled and than aspired. First two doses were pro-
cessed for differential cell counts, with the use of May-
Gru¨nwald and Giemsa-Romanowsky stains. The third dose
of BALF underwent cytometric investigation. Mononuclear
cells were stained with a commercially available conju-
gated and unconjugated mAbs that belonged to the Becton
Dickinson series. They included: CD3, CD4, CD8, HLA-DR
and isotype matched controls. The BALF specimens were
analysed in the cytometer Cytomics FC 500 (Beckman
Coulter) using the CXP software (Beckman Coulter). Fourth
and fifth doses of BALF were immediately centrifuged at
250 g for 5 min at room temperature to remove most of
the cells. The supernatant was centrifuged again at 500g
for 10 min at room temperature to produce completely cell-
free fluid. Then the supernatants were frozen at e80 C and
they were processed together later.
Assay
Concentrations of IL-8, ENA-78, IP-10 and I-TAC in BALF
supernatants were quantified using Fluorokine MultiAnalyte
Table 1 Demographic and clinical characteristics of the
patients.
EAA IPF
Number of patients 16 8
Gender (men/women) 3/13 6/2
Smokers/nonsmokers 2/14 1/7
FVC (L) 2.1 0.2 3.1 0.3
FVC (% pred) 72.2 4.7 86.3 6.9
FEV1 (L) 1.7 0.2 2.5 0.2
FEV1 (% pred) 72.7 4.4 88.6 7.4
FEV1/FVC 83.4 1.2 82.4 1.9
Tlco (% pred) 47.1 3.4 44.8 8.1
BALF recovery (ml) 24.6 1.9 26.8 3.0
Values are expressed as mean SEM. FVC % pred: Forced vital
capacity % predicted; FEV1 % pred: Forced expiratory volume
within the first second % predicted; Tlco % pred: carbon
monoxide transfer factor % predicted.
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(Luminex Corporation), as described previously.9 A stan-
dard curves were created for each chemokine. Detection
limit for ENA-78 was 3.60e6635 pg/mL, for IL-8 0.32e
2789 pg/mL and for IP-10 0.15e2267 pg/mL and for I-TAC
0e842 pg/mL. Intra- and inter-assay variability of the
assays was provided by the manufacturer.
HRCT scoring system (Table 2)
HRCT scans were performed using the Somatom Sensation
Four (Siemens, Germany) scanner. They were evaluated by
an experienced radiologist using the modified scoring
system by Gay S.10 The radiologist scored alveolar and
interstitial scores at four levels of the right and left lung.
These scores were summed for each patient and the
average interstitial and alveolar scores were calculated.
Analysis
BMDP-PC 90 statistical software was used for statistical
analysis. As for the statistical methods, Spearman’s
nonparametric correlation test (r) was applied. p levelsTable 2 Evaluation of HRCT scans, the alveolar and interstitial
Alveolar score
0 No alveolar disease
1 GGO involving 0-4% of the lung parenchyma
2 GGO involving up to 5e24% of the lung parenchyma
3 GGO involving 25e49% of the lung parenchyma
4 GGO involving 50e74% of the lung parenchyma
5 GGO involving 75e100% of the lung parenchyma
Alveolar score e inflammatory activity of the diseaseZGGO e glass gr
seen in the chronic forms of EAA and in IPFZ linear opacities, honey<0.05 were regarded as significant. Mean values of che-
mokines in BALF, expression of CXCR receptors on CD4þ T
cells and HRCT scores in the different groups were
compared by the KruskaleWallis test. Data are expressed as
a mean SEM.
Results
The demographic and clinical characteristics of the
patients are shown in Table 1.
BALF differential cell counts and expression of chemo-
kine receptors CXCR3 and CXCR2 on CD4þ T cells are shown
in Table 3. We found no significant difference in BALF
differential cell counts including CD4þ/CD8þ T cells ratio
and CXCR3 as well as CXCR2 expression on CD4þ T cells
between chronic EAA and IPF patients. BALF chemokine
levels are shown in the Table 4. There was no significant
difference in the BALF chemokine levels between the EAA
and IPF group. Mean HRCT alveolar score in the EAA group
was 2.5 0.4. HRCT alveolar score in the IPF group was
significantly lower (1.0 0.4, p< 0.01). HRCT interstitial
score in EAA group (1.9 0.33) did not significantly differ
from that in IPF group (2.6 0.46).
There was a negative correlation between HRCT alveolar
score and CD4þ/CD8þ T cells ratio in BAL fluid in EAA group
(p< 0.01) (Fig. 1), while we observed no such correlation in
the IPF group. HRCT interstitial score in EAA patients
positively correlated with the percentage of neutrophils in
BALF (0.05) (Fig. 2) and the IL-8 BALF concentration
(p< 0.01) (Fig. 3).
There was a positive correlation between the IL-8 BALF
concentration and HRCT alveolar score (p< 0.01) (Fig. 4)
and between HRCT interstitial score and percentage of
neutrophils in BALF in IPF patients (p< 0.01) (Fig. 5). We
found no correlation between CXCR2 expression on BALF
CD4þ T cells and HRCT interstitial as well as alveolar score
in IPF group. We have not observed any correlation
between the percentage of neutrophils and the concen-
trations of IL-8 and ENA-78 in the BALF of IPF and EAA
patients.
There was no correlation between HRCT scores and both
expression of CXCR3 on CD4þ T cells and BALF angiostatic
chemokine concentration in EAA and IPF group.scoring system.
Interstitial score
0 No interstitial disease
1 Interlobular
septa thickening, no discrete honeycombing
2 Honeycombing
involving up to 0e24% of the lung parenchyma
3 Honeycombing
involving 25e49% of the lung parenchyma
4 Honeycombing
involving 50e74% of the lung parenchyma
5 Honeycombing
involving 75e100% of the lung parenchyma
ound opacity. Interstitial score e fibrotic changes, predominantly
combing.
Table 3 BALF differential cell counts and expression of
chemokine receptors CXCR3 and CXCR2 on CD4þ T cells.
EAA IPF
AM 51.6 7.8 51.8 13.3
Ly 24.6 6.6 30.0 10.8
PMN 19.0 7.3 13.8 8.1
Eos 4.8 2.0 5.1 3.5
CD4/CD8 2.1 0.6 2.3 0.4
CXCR3 5.3 1.6 1.5 0.6
CXCR2 3.5 1.2 0.74 0.2
Values are expressed asmean SEM. AMe alveolarmacrophage,
Ly e lymphocyte, PMN e polymorphonuclear, Eos e eosinophil.
No significant differences were found in all above mentioned
parameters between both groups.
r = 0,64
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Figure 1 Negative correlation between HRCT alveolar score
and CD4þ/CD8þ T cells ratio in BAL fluid in EAA group.
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The chronic form of EAA is sometimes difficult to be
distinguished from IPF. In advanced diseases, where fibrotic
changes predominate, the IPF and EAA histology patterns
are both represented with usual interstitial pneumonitis
(UIP).11 UIP consists of a temporal heterogeneity of lung
tissue histological changes. Areas of fibroblastic foci
resulting from recent active fibrosis and honeycombing
cysts representing older fibrotic lesions are both present.
This suggests that the lung have been subjected to multiple
hits. While in IPF neither the initial event nor the other
harmful events are known, in EAA appropriate inhalation
antigen is clearly responsible for the injury and perpetua-
tion of fibrosis.
The aim of the presented study was to document, if
there are any differences in BALF chemokine and chemo-
kine receptor profiles between these disorders. We exam-
ined BALF levels of I-TAC/CXCL11, IP-10/CXCL10, IL-8/
CXCL8 and ENA-78/CXCL5 of patients with chronic EAA and
IPF. We investigated a relationship between the levels of
chemokines in BALF, expression of appropriate chemokine
receptors on CD4þ T cells and HRCT score.
Chronic EAA was found to differ from the subacute and
acute form of the disease. It has been widely accepted,
that low CD4þ/CD8þ T cells ratio in BALF is lower in acute
and subacute forms of EAA.6 Chronic EAA was revealed to
exhibit normal or higher CD4þ/CD8þ T cells ratio in the
BALF. Our results correspond with this observation, since
we demonstrated negative correlation between HRCT
alveolar score and CD4þ/CD8þ T cells ratio in the BALF of
chronic EAA patients.12
IL-8 as well as ENA-78 was reported to be involved in the
IPF pathogenesis. Both belong to the angiogenic chemokinesTable 4 BALF chemokine levels.
EAA IPF
IP-10 137.9 93.0 56.5 41.4
I-TAC 10.0 9.0 0.7 0.4
IL-8 96.7 30.7 44.6 14.5
ENA-78 54.0 11.9 74.6 27.0
Values are expressed in pg/L as mean SEM.family. It is believed that angiogenesis plays an important
role in the development of lung fibrosis.13 IL-8 was also
reported to play an important role in pathogenesis of EAA.4
To our knowledge, no studies concerning the role of ENA-78 in
the development of EAA have been published to date. We
found no significant difference in the IL-8 and ENA-78 BALF
concentrations of patients with EAA and IPF, even though
higher BALF concentrations of IP-10, I-TAC and IL-8 in EAA
patients and higher ENA-78 BALF concentration in IPF group
are indicated. This finding may document, that both IL-8 and
ENA-78 play role in the development of lung fibrosis in
chronic EAA patients.
IL-8 is the main chemotactic factor for neutrophils and
ENA-78 plays pivotal role in angiogenesis.14 There are few
reports in the literature concerning EAA and angiogenesis.
Pathological angiogenesis occurs during chronic inflamma-
tion, which is radiologically quantified by the means of
HRCT alveolar score. Since EAA patients have significantly
higher HRCT alveolar score than the IPF group (2.5 0.4
versus 1.0 0.4, p< 0.01), we may speculate that EAA
patients display angiogenic activities mediated through
ENA-78/CXCR2 axis in the early inflammatory phase of
disease, while angiogenesis need not play the major role
during the development of irreversible lung fibrosis. We
suggest ENA-78 as the marker of at least partial reversibility
of the lung impairment in the EAA patients.
Nevertheless, pathogenesis of lung fibrosis and angiogen-
esis is complex and cannot be attributed only to the CXCR2/
CXCR2 ligand axis. This may explain, why no correlation
between BALF CXCR2 expression on CD4þ T cells and HRCT
interstitial as well as alveolar scores was founded in both
groups. Although it was documented, that blockade of CXCR2
receptor inhibits angiogenesis and the pro-angiogenic cyto-
kines production and decreases IL-8-induced endothelial cellr = 0,4
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Figure 2 Positive correlation between percentage of neutro-
phils in BALF and HRCT interstitial score in EAA patients.
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Figure 3 Positive correlation between HRCT alveolar score
and the IL-8 BALF concentration in EAA patients.
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Figure 5 Positive correlation between HRCT interstitial
score and percentage of neutrophils in BALF in IPF patients.
Angiogenesis and angiostasis 1655activation, an effect on neutrophils does not appear to
account for the CXCR2 blockade effects in lung fibrosis path-
ogenesis. There are different ways how neutrophils partici-
pate in the lung fibrosis developement.15,16 We found
a positive correlation between percentage of neutrophils in
BALF and HRCT interstitial score in EAA as well as in the IPF
group. Neutrophils, which are also involved in the pathogen-
esis of lung fibrosis, show an exaggerated release of oxygen
radicals when activated. The imbalance in production of
oxidant/antioxidant agents has been proposed as one of the
mechanisms of injury in IPF.17 Nevertheless, there are not any
widely accepted prognostic criteria based on BALF cell
differential counts including neutrophil count in IPF.18 Acti-
vated neutrophils loaded with matrix metalloproteinase 9
(gelatinase B) and collagenase-2 were found to play role in
lung damage and fibrotic response in chronic EAA patients.
Moreover, higher BALF neutrophil count was documented to
be a sign of irreversible lung fibrosis in EAA patiens.19 Our
results correspond with the previously reported observations
anddocument the important roleof neutrophils in IPF andEAA
development. The conclusive role of neutrophils in the path-
ogenesis of IPF and EAA needs to be established.
We have not observed any correlation between the
neutrophil cell count and the BALF IL-8 concentrations of
IPF and EAA patients. We suppose, that this may be caused
by other chemokines involved in the neutrophil chemotaxis
(e.g. CXCL1/keratinocyte-derived chemokine (KC), CXCL2/
monocyte-inhibitory protein-2 (MIP-2), and CXCL5/LPS-
induced chemokine (LIX)).20
Positive correlation was documented between the IL-8
BALF concentration andHRCTalveolar score in the IPF group.
It was showed, that the areas of ground glass seen on HRCT
scans usually represent fine lung fibrosis in IPF patients.
Minor alveolar involvement in IPF group is reflected with the
lower HRCT alveolar score observed in these patients. Wer = 0,99
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Figure 4 Positive correlation between HRCT alveolar score
and the IL-8 BALF concentration in IPF group.found no study investigating longitudinal IL-8 production in
IPF patients. It is possible, that the IL-8 expression may
fluctuate in time. We may speculate that the IL-8 expression
may vary in the early and advanced phases of IPF. Further
studies with more patients will help us to find, if IL-8 might
serve as a potential marker of early phase of IPF.
There was a positive correlation of HRCT interstitial
score and IL-8 BALF concentration in the EAA group, but no
such correlation was proven in the IPF group. It was docu-
mented, that airborne endotoxin exposure in cotton
workers leads to IL-8 concentration increase in nasal lavage
fluid.21 It is possible, that the exposition to inhalation
agents leads to simultaneous IL-8 increase in BALF of EAA
patients. These patients are known to be in continual low-
level exposure to inhalant antigens. From time to time the
exposure to provoking agent may rise. This may explain the
observed correlation between IL-8 BALF concentration and
interstitial HRCT score. On the other hand, the above
mentioned histopathological character of lesions observed
in IPF patients gives evidence for the discontinuity of
injurious moments. We suggest IL-8 as an indicator of
continuous exposition to provoking agent in EAA patients.
IP-10 and I-TAC are two angiostatic chemokines, which
share the same receptor CXCR3. The importance of CXCR3
ligand/CXCR3 axis documented the study of Strieter et al.,
who postulated, that potential defect in IPF pathogenesis
may be related to the inappropriate CXCR3/CXCR3 ligand
response to injury.22 Their study has shown, that I-TAC is
the only chemokine from the angiostatic group in IPF, which
is actually stimulated by INF-g and thus mainly attenuates
the fibrogenetic process. We found very low BALF I-TAC
concentration in both groups. Low levels of I-TAC in BALF
were documented also by Nishioka et al. They found 10-
fold-lower I-TAC than of IP-10 levels in BALF and serum of
sarcoidosis patients.23 I-TAC has 100-fold higher affinity to
CXCR3 when compared with the other CXCR3 ligands,24 thus
we cannot rule out its effect in fibrotic lung tissue even in
these low concentrations.
I-TAC was documented to play an important role in
development of acute and subacute EAA and granuloma
formation.25 To our best knowledge there is no study con-
cerning the role of I-TAC in chronic EAA development,
where granulomas are not the main pathologic feature.
Although we have found no difference between I-TAC BALF
concentrations in IPF and EAA patients, we cannot exclude
the influence of I-TAC even in concentrations under the
detection limit, which can affect our observation. Because
of very low BALF I-TAC concentration in investigated
patients, we did not try to find any correlations with other
1656 S. Martina et al.investigated parameters, since the acquired data have
been distorted.
We documented no correlation of the BALF IP-10
concentration and either HRCT alveolar or HRCT interstitial
score in both groups. Previously documented differences in
the levels and time related patterns of CXCR3 ligands may
influence our results.26
Investigated patients had different extent of lung
fibrotic and alveolar changes and they differed also in the
disease duration. They were in different stages of the
disease and the production of IP-10 may thus vary.
We conclude, that both IL-8 and ENA-78 probably play
a role in chronic EAA pathogenesis, but this role might be
different. While we suggest ENA-78 as the marker of at
least partial reversibility of the lung impairment in the EAA
patients, IL-8 could be rather an indicator of continuous
exposition to provoking agent in EAA patients. As for IPF
group, IL-8 might serve as a potential marker of early phase
of IPF. Furthermore, we suppose, that the neutrophils play
a similar role in the lung fibrosis development in both IPF
and EAA. The I-TAC BALF concentrations are very low and
generally under the detection limit of multiple cytokine
analysis. IP-10 production is the same in both studied
groups, nevertheless it does not influence the radiological
pattern of either disease.
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